These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35225472)

  • 1. Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.
    Murray NP; Villalon R; Hartmann D; Rodriguez PM; Aedo S
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):591-599. PubMed ID: 35225472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.
    Murray NP; Villalon R; Hartmann D; Rodriguez MP; Aedo S
    Colorectal Dis; 2021 Nov; 23(11):2879-2893. PubMed ID: 34473913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone.
    Murray NP; Villalon R; Orrego S; Guzman E
    Colorectal Dis; 2021 Apr; 23(4):805-813. PubMed ID: 33169474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone.
    Murray NP; Villalon R; Orrego S; Guzman E
    Asian Pac J Cancer Prev; 2021 Aug; 22(8):2391-2397. PubMed ID: 34452551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy.
    Noh OK; Oh SY; Kim YB; Suh KW
    World J Surg; 2017 Nov; 41(11):2898-2905. PubMed ID: 28707088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer.
    Lu CY; Tsai HL; Uen YH; Hu HM; Chen CW; Cheng TL; Lin SR; Wang JY
    Br J Cancer; 2013 Mar; 108(4):791-7. PubMed ID: 23422758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predicting value of dynamic alteration of blood neutrophil/lymphocyte ratio on recurrence-free survival in patients with advanced colon cancer after operation and chemotherapy].
    Li J; Jia YB; Cai CN; Guan XD; Li PP; Xie YY; Zhang BM
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Nov; 15(11):1171-4. PubMed ID: 23172532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
    JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy.
    Cha YJ; Park EJ; Baik SH; Lee KY; Kang J
    Sci Rep; 2019 Aug; 9(1):11617. PubMed ID: 31406179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.
    Murray NP; Aedo S; Villalon R; López MA; Minzer S; Muñoz L; Orrego S; Contreras L; Arzeno L; Guzman E
    Ecancermedicalscience; 2019; 13():935. PubMed ID: 31281432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
    An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
    World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
    el Aziz LM
    Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
    World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.
    Rothé F; Maetens M; Rouas G; Paesmans M; Van den Eynde M; Van Laethem JL; Vergauwe P; Deboever G; Bareche Y; Vandeputte C; Ignatiadis M; Hendlisz A
    BMC Cancer; 2019 Apr; 19(1):304. PubMed ID: 30943928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer.
    Ji WB; Hong KD; Kim JS; Joung SY; Um JW; Min BW
    Chemotherapy; 2018; 63(1):8-12. PubMed ID: 29130943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
    Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
    Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.